Skip to Content

RenovaCare Inc RCAR

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RCAR is trading at a 40% discount.
Price
$0.00
Fair Value
$5.64
Uncertainty
Extreme
1-Star Price
$6.58
5-Star Price
Economic Moat
Tbcjyz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RCAR is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.35
Bid/Ask
$0.07 / $0.10
Market Cap
$87.35
Volume/Avg
700 / 1,360

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
1

Valuation

Metric
RCAR
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
RCAR
Quick Ratio
0.06
Current Ratio
0.62
Interest Coverage
−4,984.74
Quick Ratio
RCAR

Profitability

Metric
RCAR
Return on Assets (Normalized)
−172.62%
Return on Equity (Normalized)
−585.80%
Return on Invested Capital (Normalized)
−358.50%
Return on Assets
RCAR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRgfdz$552.7 Bil
VRTX
Vertex Pharmaceuticals IncZppml$110.2 Bil
REGN
Regeneron Pharmaceuticals IncWmckkfp$105.9 Bil
MRNA
Moderna IncGhmp$37.9 Bil
ARGX
argenx SE ADRCsn$23.9 Bil
BNTX
BioNTech SE ADRGwvt$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncYnbwxk$20.5 Bil
BMRN
Biomarin Pharmaceutical IncByqqxyt$16.9 Bil
RPRX
Royalty Pharma PLC Class ABvjvbjc$13.9 Bil
INCY
Incyte CorpVgwqqv$13.7 Bil

Sponsor Center